Cargando…

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis

BACKGROUND: Linezolid has been prioritized for treating multidrug-resistant tuberculosis (MDR TB), but toxicity limits its use. We report treatment outcomes for MDR TB patients in California who received standard-dose linezolid vs those who switched to low-dose. METHODS: We include culture-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mase, Anjeli, Lowenthal, Phil, True, Lisa, Henry, Leslie, Barry, Pennan, Flood, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801093/ https://www.ncbi.nlm.nih.gov/pubmed/36601556 http://dx.doi.org/10.1093/ofid/ofac500

Ejemplares similares

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Assessing Complexity Among Patients With Tuberculosis in California, 1993–2016
por: Vaisman, Alon, et al.
Publicado: (2020)

Death With Tuberculosis in California, 1994–2008
por: Pascopella, Lisa, et al.
Publicado: (2014)

Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010–2013
por: Peralta, Gianna, et al.
Publicado: (2016)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia
por: Folan, Stephanie A, et al.
Publicado: (2018)

1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022
por: Katrak, Shereen, et al.
Publicado: (2023)

Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003–2013
por: Shah, Neha S., et al.
Publicado: (2016)

Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Safety and Outcomes of Linezolid Use for Nocardiosis
por: Davidson, Natalie, et al.
Publicado: (2020)

Health insurance, healthcare utilization and language use among populations who experience risk for tuberculosis, California 2014–2017
por: Readhead, Adam, et al.
Publicado: (2022)

Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis
por: Salindri, Argita D., et al.
Publicado: (2016)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Association of Area-Based Socioeconomic Measures with Tuberculosis Incidence in California
por: Bakhsh, Yasser, et al.
Publicado: (2022)

A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015
por: Oh, Peter, et al.
Publicado: (2017)

Tuberculosis Treatment Managed by Providers outside the Public Health Department: Lessons for the Affordable Care Act
por: Ehman, Melissa, et al.
Publicado: (2014)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

1392. Tuberculosis Disease in Recipients of Organ-Transplantation, California 2010–2017
por: Katrak, Shereen, et al.
Publicado: (2019)

Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus
por: Greene, Matthew H, et al.
Publicado: (2018)

Sociodemographic Characteristics, Comorbidities, and Mortality Among Persons Diagnosed With Tuberculosis and COVID-19 in Close Succession in California, 2020
por: Nabity, Scott A., et al.
Publicado: (2021)

Getting to Zero: Tuberculosis Elimination in California
por: Barry, Pennan M., et al.
Publicado: (2016)

Laboratory-based study of drug resistance and genotypic profile of multidrug-resistant tuberculosis isolates in Salvador, Bahia, Brazil
por: Sousa, Erivelton de Oliveira, et al.
Publicado: (2022)

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies
por: Garcia-Prats, Anthony J., et al.
Publicado: (2019)

Cryptic Resistance Mutations Associated With Misdiagnoses of Multidrug-Resistant Tuberculosis
por: Cancino-Muñoz, Irving, et al.
Publicado: (2019)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Introduction and evaluation of multidrug-resistant tuberculosis supplemental surveillance in the United States()
por: Belanger, Annie, et al.
Publicado: (2019)

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
por: Sabur, Natasha F., et al.
Publicado: (2021)

Analysis of catastrophic costs incurred by patients with multidrug-resistant tuberculosis in an outpatient clinic in the state of Rio de Janeiro
por: de Medeiros, Regielle Luiza, et al.
Publicado: (2023)

Pediatric tuberculosis consultations across 5 CDC regional tuberculosis training and medical consultation Centers()
por: Mase, Anjeli, et al.
Publicado: (2018)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
por: Dorazio, Joshua, et al.
Publicado: (2023)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dposcrct5ogc6qq5n4osrl2p8n